BillionToOne (BLLN) Q1 2026: 84% Revenue Surge Accelerates Market Leadership with 73% Gross Margin
BillionToOne delivered a commanding 84% year-over-year revenue increase driven by robust test volume growth and significant ASP expansion, while achieving a rare combination of high growth and profitability. The company’s innovative prenatal and oncology molecular diagnostics platforms, supported by expanding payer contracts, underpin sustained margin expansion and a raised full-year revenue outlook. Investors should watch for continued oncology ramp and UnityConfirm’s market impact as key growth levers.
Summary
- Platform Differentiation Strengthened: Launch of UnityConfirm sets a new standard in non-invasive prenatal confirmation testing.
- Robust Commercial Execution: Accelerating test volumes and expanding payer contracts drive strong revenue and margin expansion.
- Profitability with Growth: Sustained operating margin and cash flow generation at scale uncommon in high-growth molecular diagnostics.
Business Overview
BillionToOne is a molecular diagnostics company focused on developing advanced genetic tests using its patented Quantitative Counting Templates (QCT) technology, which enables single-molecule precision DNA counting. The company operates primarily in two segments: prenatal diagnostics, including non-invasive prenatal testing (NIPT) and fetal cell-based confirmation assays; and oncology diagnostics, encompassing liquid biopsy tests for cancer detection and monitoring. Revenue is generated from clinical testing services and clinical trial support, with growth driven by test volume increases and expanded reimbursement coverage.
Performance Analysis
The first quarter of 2026 marked a milestone for BillionToOne with total revenue reaching $108.4 million, an 84% increase year-over-year fueled by a 44% rise in test volume and a 28% uplift in average selling price (ASP) per test to $571. Prenatal testing, the largest segment, grew 72% to $96.5 million, reflecting strong adoption of new fetal antigen tests and expanded payer contracts. Oncology revenues surged nearly 400% to $10.7 million, illustrating early success in the high-growth cancer diagnostics market.
Gross margin expanded significantly to 73%, up 9 percentage points from the prior year, driven by ASP growth and operational efficiencies, even as oncology tests with higher costs gained share. Operating expenses rose 52% but declined as a percentage of revenue, supporting a 16% operating margin and positive net income of $18 million. Cash flow from operations minus capital expenditures was $11 million, underscoring disciplined capital management amid aggressive growth.
- Volume and ASP Synergy: Test volume growth combined with ASP expansion underpinned robust revenue acceleration.
- Margin Expansion Despite Mix Shift: Oncology’s higher cost profile moderated margin gains but overall gross margins improved materially.
- Profitability at Scale: Operating leverage and cost control yielded GAAP profitability rare for a company at this growth stage.
This performance validates the company’s scalable model and positions BillionToOne for sustained growth in large addressable markets.
Executive Commentary
"Our first quarter performance underscores the continued momentum we are building through our differentiated technology platform, category-defining products, and disciplined execution. We remain focused on addressing some of healthcare’s most complex challenges and believe we are only beginning to realize the full potential of our platform."
Ozan Tay, Co-founder & Chief Executive Officer
"We delivered a strong combination of 84% revenue growth with 16% operating margin and 24% adjusted EBITDA margin, while expanding our cash position to $537 million. Our balance sheet positions us for strong growth as we continue to invest in our commercial team and product innovation."
Ross Taylor, Chief Financial Officer
Strategic Positioning
1. Innovation Leadership with UnityConfirm
The launch of UnityConfirm, the first non-invasive fetal cell-based confirmation assay, addresses a critical unmet need by providing a safer alternative to invasive diagnostic procedures for high-risk pregnancies. This product leverages the patented fetal cell capture technology to isolate intact fetal cells, offering 100% fetal fraction and 100% concordance with invasive diagnostics. UnityConfirm is expected to enhance differentiation of the Unity prenatal portfolio and drive frontline adoption of the company’s aneuploidy screening.
2. Expanding Market Access Through Payer Contracts
BillionToOne significantly expanded its in-network coverage, notably securing a contract with Anthem, increasing total contracted lives to 300 million in the U.S. This broad access reduces friction for providers and patients, enabling higher and more predictable ASPs. The company signs 5 to 10 new contracts monthly, which is a key driver of ASP growth and volume expansion, especially in prenatal diagnostics.
3. Oncology Growth and Product Pipeline Execution
Oncology revenue grew nearly fivefold, driven by increased adoption of North Star Select and Response tests, and recent launches of pharmacogenomics and clonal hematopoiesis assays. The tumor-naive minimal residual disease (MRD) test remains on track for launch by year-end, with data to be released concurrently. This tumor-naive approach targets broader community oncologist adoption beyond academic centers, positioning BillionToOne for substantial long-term growth in cancer monitoring.
4. Operational Discipline Supporting Profitability
Despite rapid growth and new product launches, the company maintained stable cost of goods sold (COGS) per test and improved gross margins. Operating expenses increased but at a slower rate than revenue, reflecting disciplined investment in sales, R&D, and clinical evidence. This balance enabled a rare combination of high growth and profitability, with positive operating income and free cash flow generation.
5. Long-Term Vision for Market Leadership
BillionToOne’s strategy focuses on building a category-defining company with scalable technology platforms, expanding product portfolios, and broad payer coverage. The company aims to become an S&P 500 member by continuing to innovate, grow revenue, and maintain profitability, supported by a strong balance sheet and efficient operations.
Key Considerations
BillionToOne’s Q1 results reflect a well-executed growth strategy anchored in technological innovation and market access expansion. Investors should consider the following:
- UnityConfirm’s Market Impact: While the direct revenue contribution may be modest due to limited eligible patients, its strategic value in differentiating the prenatal platform and driving upstream test volume is significant.
- Oncology ASP and Margin Dynamics: Oncology tests currently have higher costs and lower margins but offer outsized growth potential; Medicare coverage of North Star Response later this year is expected to boost ASPs and margins.
- Seasonality in Volume: Anticipate a slower Q4 due to holidays and fewer accessioning days, with modest sequential growth expected in Q2 and Q3.
- Accounts Receivable Fluctuations: Increased AR reflects new payer contracts and timing of reimbursements, expected to normalize by Q3.
- Clinical Trial Timelines: The large-scale UnityConfirm study may take one to three years due to declining invasive diagnostic procedures, impacting timing of definitive data readouts.
Risks
BillionToOne faces risks including potential delays in payer coverage expansions, variability in reimbursement rates, and the operational challenges of scaling oncology offerings with higher costs. The lengthy clinical trial for UnityConfirm introduces timing uncertainty for validation data. Additionally, competitive pressures in molecular diagnostics and regulatory developments could impact market share and growth trajectories.
Forward Outlook
For Q2 2026, BillionToOne expects modest sequential volume growth with seasonally slower Q4. The company raised full-year 2026 revenue guidance to $450 million to $465 million, reflecting 48% to 52% growth over 2025, driven primarily by ASP increases from new payer contracts and strong Q1 momentum.
- Revenue growth driven by ASP expansion and sustained test volume increases.
- Gross margins expected to remain above 70%, with potential quarterly variability.
Management anticipates continued profitability at levels approaching current margins despite ongoing investments in sales, R&D, and clinical programs.
Takeaways
BillionToOne’s Q1 results demonstrate the power of its differentiated molecular diagnostics platform coupled with disciplined execution and expanding market access. Key takeaways include:
- Strong Revenue and Margin Expansion: The company’s ability to grow revenue by 84% while expanding gross margins to 73% underscores operational leverage and pricing power in a large and growing market.
- Strategic Innovation Driving Differentiation: UnityConfirm’s launch addresses a longstanding clinical gap, reinforcing BillionToOne’s leadership in prenatal diagnostics and enhancing the Unity product ecosystem.
- Oncology as a Growth Engine: Rapid oncology revenue growth and the upcoming tumor-naive MRD launch position the company to capture significant market share in cancer monitoring, a key future growth vector.
Conclusion
BillionToOne’s first quarter results reflect a rare combination of rapid growth, expanding margins, and profitability, driven by innovative technology and strong commercial execution. The raised guidance and strategic initiatives in prenatal and oncology diagnostics position the company for continued leadership and value creation in molecular diagnostics.
Industry Read-Through
BillionToOne’s performance highlights the increasing importance of integrated molecular diagnostic platforms that combine high sensitivity with broad payer coverage. The successful rollout of non-invasive confirmation assays signals a potential shift in prenatal testing paradigms industry-wide. Additionally, the rapid adoption of tumor-naive MRD tests underscores a broader trend toward accessible, community-based cancer monitoring solutions. Competitors and investors should note the critical role of payer contracts and operational discipline in scaling high-growth diagnostics businesses profitably.